Recent News

• 12.09.2025 - Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel
• 11.24.2025 - Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder
• 11.17.2025 - Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA™ (cyclobenzaprine HCl sublingual tablets) as a First-in-Class Fibromyalgia Treatment
• 11.10.2025 - Tonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights
• 11.10.2025 - Tonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights
• 11.06.2025 - Tonix Pharmaceuticals to Participate in the Stifel 2025 Healthcare Conference
• 10.28.2025 - Tonix Pharmaceuticals Announces Presentation at BIO-Europe 2025
• 10.28.2025 - Tonix Pharmaceuticals Announces Presentation at BIO-Europe 2025
• 10.27.2025 - Tonix Pharmaceuticals Presented Data on Tonmya™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2025 American College of Rheumatology (ACR) Convergence
• 10.22.2025 - Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix’s Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts General Hospital

Recent Filings

• 11.24.2025 - 8-K Current report
• 11.21.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 11.21.2025 - 8-K Current report
• 11.18.2025 - 8-K Current report
• 11.17.2025 - 8-K Current report
• 11.10.2025 - 8-K Current report
• 11.10.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 10.31.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 10.27.2025 - 8-K Current report